Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILENT TECHNOLOGIES, INC.A · Entity 3062 | Director | March 19, 2026 | March 23, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | Director | May 18, 2020 | May 21, 2020 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | February 24, 2025 | February 25, 2025 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILENT TECHNOLOGIES, INC.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,800.047 |
Reported balance
After 2026-03-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 2,158 · Balance 22,800.047 F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. F2: 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 23,857.047 |
Reported balance
After 2026-03-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-19 · Grant · Acquired 1,057 · Balance 23,857.047 F3: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. |
| Common StockSEC Table I · non-derivative | IndirectGeorge A. Scangos and Leslie S. Wilson Family Trust | 17,893 |
Reported balance
Holding disclosure · report date 2026-03-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 17,893 F4: Shares held in the George A. Scangos and Leslie S. Wilson Family Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock.
F2: 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.
F3: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors.
F4: Shares held in the George A. Scangos and Leslie S. Wilson Family Trust.
EXELIXIS, INC.
Report date May 18, 2020 · Filed May 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 714,717 |
Reported balance
After 2020-05-18 transaction · row 1
1 source rowRow 1 · 2020-05-18 · Sale · Disposed 75,000 · Balance 714,717 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.59 to $26.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust (JS) | 8,963 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,963 F3: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Jennifer Scangos Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust (KS) | 8,963 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,963 F4: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Katherine Scangos Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,669 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,669 F5: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 18, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.
F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.59 to $26.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Jennifer Scangos Trust.
F4: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Katherine Scangos Trust.
F5: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 18, 2020.
Vir Biotechnology, Inc.
Report date February 24, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 698,239 |
Reported balance
After 2025-02-24 transaction · row 1
1 source rowRow 1 · 2025-02-24 · Sale · Disposed 10,056 · Balance 698,239 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,151,730 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,151,730 F2: The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,151,730 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,151,730 F4: The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 33,629 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 33,629 F5: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 179,930 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 179,930 F6: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 598,270 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 598,270 F3: The shares are held by the spouse of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F2: The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F3: The shares are held by the spouse of the Reporting Person.
F4: The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F5: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
F6: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
Voyager Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2036-06-09 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2019 Filed Jun 6, 2019 00:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,000 | $20.00 | $300,000.00 |
DisclosureSEC source: 0000939767-19-000138 · wf-form4_155978050296245.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| June 03, 2019 Filed Jun 6, 2019 00:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $19.61 | $490,250.00 |
DisclosureSEC source: 0000939767-19-000138 · wf-form4_155978050296245.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.45 to $19.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 42,641 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000132 · wf-form4_155874467224174.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 21, 2019 Filed May 23, 2019 00:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000121 · wf-form4_155857275798722.xml · derivative · entry 5 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| May 21, 2019 Filed May 23, 2019 00:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000121 · wf-form4_155857275798722.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,248,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 4, 2019 00:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,000 | $20.00 | $300,000.00 |
DisclosureSEC source: 0000939767-19-000111 · wf-form4_155693115338573.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.02. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| May 01, 2019 Filed May 4, 2019 00:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $19.75 | $493,750.00 |
DisclosureSEC source: 0000939767-19-000111 · wf-form4_155693115338573.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,248,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.60 to $19.84. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 5,000 | $25.03 | $125,150.00 |
DisclosureSEC source: 0000939767-19-000082 · wf-form4_155433633161299.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.06. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $24.02 | $960,800.00 |
DisclosureSEC source: 0000939767-19-000082 · wf-form4_155433633161299.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.91 to $24.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 18:30 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,254.87 | $82.00 | $102,899.34 |
DisclosureSEC source: 0001127602-19-012831 · form4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,698.887 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors that vest in 25% quarterly increments, with the first vesting on the date of grant. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 18:30 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 2,823 | $82.00 | $231,486.00 |
DisclosureSEC source: 0001127602-19-012831 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,444.017 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 47.161 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. Read SEC document |
| March 14, 2019 Filed Mar 16, 2019 00:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0000939767-19-000067 · wf-form4_155269591670448.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 01, 2019 Filed Mar 2, 2019 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $22.66 | $906,400.00 |
DisclosureSEC source: 0000939767-19-000054 · wf-form4_155148942126390.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,323,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.45 to $22.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $23.53 | $941,200.00 |
DisclosureSEC source: 0000939767-19-000018 · wf-form4_154906938797191.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.43 to $23.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| January 03, 2019 Filed Jan 5, 2019 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 96 | $20.00 | $1,920.00 |
DisclosureSEC source: 0000939767-19-000004 · wf-form4_154665106994303.xml · nonDerivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,403,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. Read SEC document |
| January 02, 2019 Filed Jan 5, 2019 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 39,904 | $19.64 | $783,714.56 |
DisclosureSEC source: 0000939767-19-000004 · wf-form4_154665106994303.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,403,127 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.18 to $20.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| December 15, 2018 Filed Jan 5, 2019 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000004 · wf-form4_154665106994303.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,443,031 Read SEC document |
| December 15, 2018 Filed Jan 5, 2019 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 4,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000004 · wf-form4_154665106994303.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,452,331 Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $21.16 | $846,400.00 |
DisclosureSEC source: 0000939767-18-000246 · wf-form4_154388540385711.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,456,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.76 to $21.57. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 8,500 | $20.00 | $170,000.00 |
DisclosureSEC source: 0000939767-18-000246 · wf-form4_154388540385711.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,496,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 29, 2018 Filed Dec 4, 2018 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 6,500 | $20.00 | $130,000.00 |
DisclosureSEC source: 0000939767-18-000246 · wf-form4_154388540385711.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,505,481 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 10,000 | $14.14 | $141,400.00 |
DisclosureSEC source: 0000939767-18-000223 · wf-form4_154120341758722.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,511,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.92 to $14.22. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,000 | $15.00 | $225,000.00 |
DisclosureSEC source: 0000939767-18-000223 · wf-form4_154120341758722.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,521,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $17.86 | $446,500.00 |
DisclosureSEC source: 0000939767-18-000210 · wf-form4_153861195132768.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,536,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.67 to $17.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 23:40 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $16.85 | $421,250.00 |
DisclosureSEC source: 0000939767-18-000204 · wf-form4_153800521414604.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,561,981 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.71 to $16.94. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| August 10, 2018 Filed Aug 11, 2018 01:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 33,333 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000939767-18-000182 · wf-form4_153395071513855.xml · derivative · entry 7 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2019-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 100,000 shares of Exelixis, Inc. common stock, became exercisable as to 25,000 shares on February 26, 2010, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the original grant date (February 26, 2009). The option ceased vesting on July 15, 2010, in connection with the Reporting Person's resignation as President and Chief Executive Officer of Exelixis, Inc., at which time the option was exercisable as to as to 33,333 shares of Exelixis, Inc. common stock. Read SEC document |
| August 10, 2018 Filed Aug 11, 2018 01:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-18-000182 · wf-form4_153395071513855.xml · derivative · entry 6 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became exercisable as to 50,000 shares on December 16, 2009, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the original grant date (December 16, 2008). The option ceased vesting on July 15, 2010, in connection with the Reporting Person's resignation as President and Chief Executive Officer of Exelixis, Inc., at which time the option was exercisable as to as to 75,000 shares of Exelixis, Inc. common stock. Read SEC document |
| August 10, 2018 Filed Aug 11, 2018 01:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 33,333 | $4.42 | $147,331.86 |
DisclosureSEC source: 0000939767-18-000182 · wf-form4_153395071513855.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,586,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2018 Filed Aug 11, 2018 01:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 75,000 | $5.04 | $378,000.00 |
DisclosureSEC source: 0000939767-18-000182 · wf-form4_153395071513855.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,553,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2018 Filed May 25, 2018 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 31,167 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000105 · wf-form4_152720773417488.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,167 Underlying: Common Stock · 31,167 shares Expires 2025-05-23 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 15, 2018 Filed May 16, 2018 23:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0000939767-18-000083 · wf-form4_152651511327180.xml · derivative · entry 5 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2011. Read SEC document |
| May 15, 2018 Filed May 16, 2018 23:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $11.66 | $174,900.00 |
DisclosureSEC source: 0000939767-18-000083 · wf-form4_152651511327180.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,478,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 22:36 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,438.063 | $67.47 | $97,026.11 |
DisclosureSEC source: 0001127602-18-012680 · form4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,573.856 F3 · shares: Shares of the Company's common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors that vest in 25% quarterly increments, with the first date of vesting being the date of grant. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 22:36 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 2,876 | $67.47 | $194,043.72 |
DisclosureSEC source: 0001127602-18-012680 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,135.793 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 6.877 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 23,491 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000116 · wf-form4_149584634971456.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,491 Underlying: Common Stock · 23,491 shares Expires 2024-05-24 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 22:52 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 3,866 | $53.05 | $205,091.30 |
DisclosureSEC source: 0001127602-17-012252 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,252.916 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · balance_after: 8.488 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 356 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0000939767-16-000288 · wf-form4_148115541665566.xml · derivative · entry 9 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 356 shares Expires 2016-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became exercisable as to 100,000 shares on December 8, 2007, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the original grant date (December 8, 2006). The option ceased vesting on July 15, 2010, in connection with the Reporting Person's resignation as President and Chief Executive Officer of Exelixis, Inc., at which time the option was exercisable as to as to 358,332 shares of Exelixis, Inc. Common Stock. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 176 | $17.90 | $3,150.40 |
DisclosureSEC source: 0000939767-16-000288 · wf-form4_148115541665566.xml · nonDerivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,463,648 Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 356 | $8.99 | $3,200.44 |
DisclosureSEC source: 0000939767-16-000288 · wf-form4_148115541665566.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,463,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2016 Filed Dec 8, 2016 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 357,976 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0000939767-16-000288 · wf-form4_148115541665566.xml · derivative · entry 8 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356 Underlying: Common Stock · 357,976 shares Expires 2016-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became exercisable as to 100,000 shares on December 8, 2007, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the original grant date (December 8, 2006). The option ceased vesting on July 15, 2010, in connection with the Reporting Person's resignation as President and Chief Executive Officer of Exelixis, Inc., at which time the option was exercisable as to as to 358,332 shares of Exelixis, Inc. Common Stock. Read SEC document |
| December 05, 2016 Filed Dec 8, 2016 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 204,718 | $17.81 | $3,646,027.58 |
DisclosureSEC source: 0000939767-16-000288 · wf-form4_148115541665566.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,463,468 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.45 to $18.00. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| December 05, 2016 Filed Dec 8, 2016 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 357,976 | $8.99 | $3,218,204.24 |
DisclosureSEC source: 0000939767-16-000288 · wf-form4_148115541665566.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,668,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,596 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.